AVITA Medical, Inc. RCEL
AVITA Medical is a leading therapeutic acute wound care company delivering transformative solutions designed to optimize wound healing, accelerate patient recovery, and improve clinical and economic outcomes across the continuum of acute wound management. Our technologies address critical healing needs arising from burns, traumatic injuries and surgical repairs, through a portfolio of proprietary and complementary products that support wound bed preparation, definitive closure, and recovery.
Our current commercial portfolio includes RECELL® ("RECELL"), and two complementary wound care products, PermeaDerm® and Cohealyx, which together support a comprehensive standard of care for acute wounds.
Valuation FY2025 figures against the last close
Where the revenue comes from as reported in the latest 10-K
Revenue by geography
- United States
- Japan
- Other
| Region | FY2025 | FY2024 |
|---|---|---|
| United States | $68.8M | $62.2M |
| Japan | $2.1M | $1.4M |
| Other | $735.0K | $663.0K |
As the company reported it, from the “Reporting Segment and Geographic Information - Schedule Of Revenue By Region And Customer Location And Customer Type And Commercial Revenue By Product (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $70.9M | $63.9M | $50.1M | $34.4M | $29.2M | $14.3M | $5.5M | $929.0K | — |
| Cost of revenue | $12.8M | $9.1M | $7.8M | $6.0M | $5.9M | $3.0M | $1.3M | $546.0K | — |
| Gross profit | $58.8M | $55.2M | $42.4M | $28.4M | $23.3M | $11.3M | $4.2M | $383.0K | — |
| R&D | $20.8M | $20.4M | $20.8M | $13.9M | $14.8M | $9.2M | $8.0M | $6.3M | — |
| SG&A | $27.4M | $33.2M | $28.3M | $23.3M | $22.4M | $33.0M | $15.1M | $9.4M | — |
| Total operating expenses | $101.3M | $111.8M | $86.4M | $59.1M | $51.9M | $57.9M | $35.7M | $22.0M | — |
| Operating income | -$42.5M | -$56.6M | -$42.7M | -$27.5M | -$26.5M | -$42.7M | -$25.5M | -$13.8M | — |
| Interest expense | $5.0M | $5.4M | $1.1M | $16.0K | $22.0K | $33.0K | $27.0K | $21.0K | — |
| Pre-tax income | -$48.6M | -$61.8M | -$35.3M | -$26.6M | -$26.5M | -$42.0M | -$25.2M | -$13.8M | — |
| Income tax | $11.0K | $54.0K | $66.0K | $36.0K | $38.0K | $4.0K | $121.0K | $1.1M | — |
| Net income | -$48.6M | -$61.8M | -$35.4M | -$26.7M | -$26.6M | -$42.0M | -$25.1M | -$12.7M | — |
| EPS, basic | -1.74 | -2.39 | -1.40 | 1.07 | 1.17 | 2.07 | 1.56 | 1.37 | — |
| EPS, diluted | -1.74 | -2.39 | -1.40 | 1.07 | 1.17 | 2.07 | 1.56 | 1.37 | — |
| Shares, diluted (wtd. avg.) | 27.9M | 25.9M | 25.3M | 25.0M | 22.7M | 20.3M | 16.1M | 9.3M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $10.2M | $14.1M | $22.1M | $18.2M | $55.7M | $73.8M | $20.4M | $11.0M | $2.9M |
| Short-term investments | $7.9M | $21.8M | $66.9M | $61.2M | $29.6M | — | — | — | — |
| Receivables | $9.1M | $11.8M | $7.7M | $3.5M | $3.5M | $2.1M | $1.4M | — | — |
| Inventory | $6.9M | $7.3M | $5.6M | $2.1M | $1.6M | $1.1M | $742.0K | — | — |
| Total current assets | $35.5M | $57.0M | $104.0M | $87.5M | $121.3M | $78.4M | $24.1M | — | — |
| Property, plant and equipment | $8.6M | $10.0M | $1.9M | $1.2M | $1.5M | $1.4M | $1.3M | — | — |
| Other intangibles | $5.6M | $5.6M | $487.0K | $465.0K | $472.0K | $364.0K | $225.0K | — | — |
| Total assets | $56.4M | $79.7M | $111.6M | $98.3M | $125.5M | $82.5M | $25.8M | — | — |
| Accounts payable | $9.0M | $6.3M | $3.8M | $3.0M | $3.1M | $4.3M | $1.9M | — | — |
| Short-term debt | $43.0M | $0 | — | — | — | — | — | — | — |
| Total current liabilities | $62.7M | $20.2M | $13.2M | $10.7M | $7.4M | $7.7M | $4.5M | — | — |
| Long-term debt | $0 | $42.2M | $39.8M | — | — | — | — | — | — |
| Total liabilities | $73.0M | $75.0M | $61.9M | $13.0M | $9.8M | $10.1M | $5.0M | — | — |
| Retained earnings | -$408.4M | -$359.8M | -$298.0M | -$262.6M | -$221.5M | -$194.9M | -$152.8M | — | — |
| Total equity | -$16.6M | $4.5M | $49.1M | $84.7M | $104.6M | $72.4M | $20.8M | $14.0M | $3.9M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$31.2M | -$48.9M | -$38.0M | -$19.1M | -$25.9M | -$22.7M | -$19.2M | -$13.0M | — |
| Depreciation and amortisation | $2.3M | $1.1M | $632.0K | $568.0K | $715.0K | $465.0K | $269.0K | $110.0K | — |
| Stock-based compensation | $9.5M | $13.5M | $8.4M | $7.0M | $5.7M | $16.5M | $1.9M | $1.4M | — |
| Capital expenditure | $1.0M | $9.2M | $1.4M | $452.0K | $894.0K | $590.0K | $1.0M | $365.0K | — |
| Investing cash flow | $12.5M | $37.4M | $1.6M | -$19.3M | -$1.2M | -$847.0K | -$1.2M | -$365.0K | — |
| Financing cash flow | $14.9M | $3.5M | $40.4M | $900.0K | $64.0M | $77.1M | $29.7M | $21.3M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-049031.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $929.0K | $5.5M | $14.3M | $29.2M | $34.4M | $50.1M | $63.9M | $70.9M |
| Gross profit | — | $383.0K | $4.2M | $11.3M | $23.3M | $28.4M | $42.4M | $55.2M | $58.8M |
| Net income | — | -$12.7M | -$25.1M | -$42.0M | -$26.6M | -$26.7M | -$35.4M | -$61.8M | -$48.6M |
Recent filings and events
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Material agreement signed Item 1.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Shareholder vote Item 5.07
- Results announced Item 2.02
- Officer or director change Item 5.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Material agreement signed Item 1.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 3841
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| SYK | STRYKER CORP | $117.81B | 36.6x | 11.2% |
| MMM | 3M CO | $89.46B | 28.9x | 1.5% |
| BSX | BOSTON SCIENTIFIC CORP | $66.22B | 23.6x | 19.9% |
| BDX | BECTON DICKINSON & CO | $54.18B | 34.2x | 8.2% |
| RMD | RESMED INC | $36.48B | 24.2x | 9.9% |
| DXCM | DEXCOM INC | $29.41B | 37.3x | 15.6% |
| MDLN | Medline Inc. | $29.20B | — | 11.5% |
| WST | WEST PHARMACEUTICAL SERVICES INC | $27.60B | 57.8x | 6.3% |